Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-082520
Filing Date
2025-06-05
Accepted
2025-06-05 17:17:25
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 26837
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 107295
3 EX-99.2 ck0000000000-ex99_2.pdf EX-99.2 207338
  Complete submission text file 0000950170-25-082520.txt   462348
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Subject) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-91490 | Film No.: 251028164
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 985 OLD EAGLE SCHOOL ROAD SUITE 511 WAYNE PA 19087
Business Address 985 OLD EAGLE SCHOOL ROAD SUITE 511 WAYNE PA 19087 (610) 766-2240
SR ONE CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001853723 (see all company filings)

EIN.: 843383413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D